AGIOS PHARMACEUTICALS, INC. Shareholders' Equity
AGIOS PHARMACEUTICALS, INC. (AGIO) had Shareholders' Equity of $1.03 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.03B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.11B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.19B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.28B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.03B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $1.11B 10-Q · filed 2026-07-30 |
| 2025-12-31 | $1.19B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $1.28B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $1.37B 10-Q · filed 2026-07-30 |
| 2025-03-31 | $1.47B 10-Q · filed 2026-07-30 |
| 2024-12-31 | $1.54B 10-Q · filed 2026-07-30 |
| 2024-09-30 | $1.63B 10-Q · filed 2025-10-30 |
| 2024-06-30 | $660.51M 10-Q · filed 2025-10-30 |
| 2024-03-31 | $743.92M 10-Q · filed 2025-10-30 |
| 2023-12-31 | $811.02M 10-K · filed 2026-02-12 |
| 2023-09-30 | $886.84M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $964.24M 10-Q · filed 2024-10-31 |
| 2023-03-31 | $1.04B 10-Q · filed 2024-10-31 |
| 2022-12-31 | $1.10B 10-K · filed 2026-02-12 |
| 2022-09-30 | $1.05B 10-Q · filed 2023-11-02 |
| 2022-06-30 | $1.12B 10-Q · filed 2023-11-02 |
| 2022-03-31 | $1.21B 10-Q · filed 2023-11-02 |
| 2021-12-31 | $1.29B 10-K · filed 2025-02-13 |
| 2021-09-30 | $1.39B 10-Q · filed 2022-11-03 |
| 2021-06-30 | $1.72B 10-Q · filed 2022-11-03 |
| 2021-03-31 | $2.30B 10-Q · filed 2022-11-03 |
| 2020-12-31 | $399.50M 10-K · filed 2024-02-15 |
| 2020-09-30 | $480.45M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $558.47M 10-Q · filed 2021-11-03 |
| 2020-03-31 | $625.30M 10-Q · filed 2021-11-03 |
| 2019-12-31 | $640.53M 10-K · filed 2023-02-23 |
| 2019-09-30 | $448.29M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $532.68M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $620.26M 10-Q · filed 2020-11-05 |
| 2018-12-31 | $687.54M 10-K · filed 2022-02-24 |
| 2018-09-30 | $760.21M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $823.14M 10-Q · filed 2019-10-31 |
| 2018-03-31 | $865.59M 10-Q · filed 2019-10-31 |
| 2017-12-31 | $375.50M 10-K · filed 2021-02-25 |
| 2017-09-30 | $449.81M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $508.99M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $307.38M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $358.59M 10-K · filed 2020-02-19 |
| 2016-09-30 | $401.45M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $289.08M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $332.37M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $345.12M 10-K · filed 2019-02-14 |
| 2015-09-30 | $375.66M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $404.17M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $426.82M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $424.37M 10-K · filed 2018-02-14 |
| 2014-09-30 | $207.75M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $200.55M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $121.34M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $131.48M 10-K · filed 2017-02-16 |
| 2013-09-30 | $142.59M 10-Q · filed 2013-11-07 |
| 2013-06-30 | -$87.05M 10-Q · filed 2013-09-05 |
| 2012-12-31 | -$72.02M 10-K · filed 2016-02-26 |
| 2011-12-31 | -$52.78M 10-K · filed 2015-02-24 |
| 2010-12-31 | -$29.59M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |